Literature DB >> 22095570

Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease.

V A Triant1, F Josephson, C G Rochester, K N Althoff, K Marcus, R Munk, C Cooper, R B D'Agostino, D Costagliola, C A Sabin, P L Williams, S Hughes, W S Post, N Chandra-Strobos, G Guaraldi, S S Young, R Obenchain, R Bedimo, V Miller, J Strobos.   

Abstract

Clinical decisions are ideally based on randomized trials but must often rely on observational data analyses, which are less straightforward and more influenced by methodology. The authors, from a series of expert roundtables convened by the Forum for Collaborative HIV Research on the use of observational studies to assess cardiovascular disease risk in human immunodeficiency virus infection, recommend that clinicians who review or interpret epidemiological publications consider 7 key statistical issues: (1) clear explanation of confounding and adjustment; (2) handling and impact of missing data; (3) consistency and clinical relevance of outcome measurements and covariate risk factors; (4) multivariate modeling techniques including time-dependent variables; (5) how multiple testing is addressed; (6) distinction between statistical and clinical significance; and (7) need for confirmation from independent databases. Recommendations to permit better understanding of potential methodological limitations include both responsible public access to de-identified source data, where permitted, and exploration of novel statistical methods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095570      PMCID: PMC3258276          DOI: 10.1093/cid/cir829

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example.

Authors:  Mirjam J Knol; Kristel J M Janssen; A Rogier T Donders; Antoine C G Egberts; E Rob Heerdink; Diederick E Grobbee; Karel G M Moons; Mirjam I Geerlings
Journal:  J Clin Epidemiol       Date:  2010-03-25       Impact factor: 6.437

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  J Clin Epidemiol       Date:  2008-04       Impact factor: 6.437

3.  Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population.

Authors:  Sylvie Lang; Murielle Mary-Krause; Laurent Cotte; Jacques Gilquin; Marialuisa Partisani; Anne Simon; Franck Boccara; Annie Bingham; Dominique Costagliola
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

4.  Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Authors:  Cindy H Brothers; Jaime E Hernandez; Amy G Cutrell; Lloyd Curtis; Mounir Ait-Khaled; Steve J Bowlin; Sara H Hughes; Jane M Yeo; Didier H Lapierre
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

5.  Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Authors:  Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

6.  Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.

Authors:  Tracie L Miller; E John Orav; Steven E Lipshultz; Kristopher L Arheart; Christopher Duggan; Geoffrey A Weinberg; Lori Bechard; Lauren Furuta; Jeanne Nicchitta; Sherwood L Gorbach; Abby Shevitz
Journal:  J Pediatr       Date:  2008-06-09       Impact factor: 4.406

7.  Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Authors:  Niels Obel; D K Farkas; G Kronborg; C S Larsen; G Pedersen; A Riis; C Pedersen; J Gerstoft; H T Sørensen
Journal:  HIV Med       Date:  2009-08-13       Impact factor: 3.180

8.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Authors: 
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

9.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

10.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

Authors:  Caroline A Sabin; Signe W Worm; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Christian Pradier; Ian Weller; Andrew N Phillips; Jens D Lundgren
Journal:  Lancet       Date:  2008-04-02       Impact factor: 202.731

View more
  9 in total

1.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

2.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

Review 3.  Quarter Century of Anti-HIV CAR T Cells.

Authors:  Thor A Wagner
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

Review 4.  HIV infection and older Americans: the public health perspective.

Authors:  John T Brooks; Kate Buchacz; Kelly A Gebo; Jonathan Mermin
Journal:  Am J Public Health       Date:  2012-06-14       Impact factor: 9.308

Review 5.  The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.

Authors:  Katherine Samaras
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

6.  The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment.

Authors:  Anthony N Muiru; Erin Madden; Ani Chilingirian; Anna D Rubinsky; Rebecca Scherzer; Richard Moore; Celia P Corona Villalobos; Jose Manuel Monroy Trujillo; Chirag R Parikh; Chi-Yuan Hsu; Michael G Shlipak; Michelle M Estrella
Journal:  HIV Med       Date:  2021-12-12       Impact factor: 3.094

7.  Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis.

Authors:  Karin A L Mueller; David B Hanna; Erik Ehinger; Xiaonan Xue; Livia Baas; Meinrad P Gawaz; Tobias Geisler; Kathryn Anastos; Mardge H Cohen; Stephen J Gange; Sonya L Heath; Jason M Lazar; Chenglong Liu; Wendy J Mack; Igho Ofotokun; Phyllis C Tien; Howard N Hodis; Alan L Landay; Robert C Kaplan; Klaus Ley
Journal:  Cardiovasc Res       Date:  2019-05-01       Impact factor: 13.081

8.  Determinants of Smoking and Quitting in HIV-Infected Individuals.

Authors:  Susan Regan; James B Meigs; Steven K Grinspoon; Virginia A Triant
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

9.  Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Authors:  Kumudhini Preethi Haran; Agnes Hajduczki; Mary S Pampusch; Gwantwa Mwakalundwa; Diego A Vargas-Inchaustegui; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.